Equites Radar

RVTY · Revvity, Inc.

Diagnostics & ResearchUnited StatesAnalyst view: Buy

$110.47

+3.18% last session

End-of-day data · updated 2026-07-28

Mildly bullish3 bullish · 1 bearish technical signals
Consensus: Buy (2.29 from 15 analysts)
To mean target: +6.0%

Market cap

$12B

Enterprise value

$15B

Trailing P/E

52.0

Forward P/E

18.5

Dividend yield

0.0%

Beta

1.09

Avg volume

1M

Employees

11K

2D change

5D change

-4.51%

10D change

-1.89%

30D change

-4.32%

60D change

3.43%

MTD change

-4.17%

YTD change

11.93%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)2.29
Covering analysts15
Mean price target$117.13
Low price target$90.00
Upside to mean target+6.0%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)55.1
50-day MA$104.60
200-day MA$98.35
Price vs 50-day MA+6.6%
Price vs 200-day MA+13.4%
MACD histogram-0.55
Volume vs 3-month avg1.0×
52w low $82.2152w high $117.58

Analyst sentiment over time — RVTY

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-07-06

Latest call per bank · past 12 months

Barclays

Equal-Weight

$105

-5.0% vs price
▲ raised from $95.00Maintains · 2026-05-07

JP Morgan

Neutral

$90.00

-18.5% vs price
▼ cut from $96.00Maintains · 2026-05-06

Goldman Sachs

Neutral

$95.00

-14.0% vs price
▼ cut from $110Maintains · 2026-04-14

Wells Fargo

Equal-Weight

$110

-0.4% vs price
▲ raised from $107Maintains · 2026-02-03

Jefferies

Hold

$105

-5.0% vs price
▲ raised from $100Maintains · 2026-02-03

Bank of America

Buy

$99.00

-10.4% vs price
▼ cut from $110Maintains · 2025-09-22

Recent rating actions

DateFirmActionRatingPrice target
2026-07-06Evercore ISI GroupMaintainsOutperform$110 $125
2026-05-07BarclaysMaintainsEqual-Weight$95.00 $105
2026-05-06JP MorganMaintainsNeutral$96.00 $90.00
2026-05-06TD CowenMaintainsBuy$115 $120
2026-05-06StifelMaintainsHold$110 $100
2026-05-04BairdMaintainsOutperform$129 $125
2026-04-14Goldman SachsMaintainsNeutral$110 $95.00
2026-04-14BarclaysDowngradeOverweightEqual-Weight$118 $95.00

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

  • RSI (14): RSI is 55 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 6.6% above the 50-day MA ($104.60).
  • Price vs 200-day MA: Trading 13.4% above the 200-day MA ($98.35).
  • MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
  • MACD (12,26,9): MACD histogram is negative (-0.55) — short-term momentum is fading.
  • 52-week range: Price sits between the 52-week low ($82.21) and high ($117.58).

RVTY Price Chart

Loading chart for RVTY

Fundamentals

Revenue (TTM)$3.0B
EBITDA$1.0B
Free cash flow$1.0B
Operating cash flow$1.0B
Book value / share$64.34
Net debt / EBITDA2.9
WACC10.0%
Revenue growth7.00%
Earnings growth4.00%

About Revvity, Inc.

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

More in Diagnostics & Research

Screen RVTY against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.